NK cell activity and methylated HOXA9 circulating tumor DNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Schjoedt Hansen, Christa Haugaard, Ole Hilberg, Anders Jakobsen, Torben Schjoedt Hansen

Research output: Contribution to journalConference abstract in journalResearchpeer-review


Background: PD-1/PD-L1 inhibitors have improved survival for patients with non-small cell lung cancer (NSCLC), but better prognostic biomarkers are needed. Methods: We prospectively collected plasma from 82 patients with NSCLC before initiating treatment with PD-1/PD-L1 inhibitors and before treatment cycles 2-4. We used the NK Vue assay to measure interferon gamma (IFNγ) as a surrogate for natural killer cell activity (NKA) with a cutoff of 250 pg/mL. Circulating tumor DNA (ctDNA) in the form of methylated HOXA9 was measured by droplet digital PCR. ctDNA status was classified as detectable or undetectable ctDNA. Results: Patients were classified into three groups according to IFNγ levels at the available time points. The NKA-low group had a persistently low level of IFNγ or dropped to and remained at a low level after baseline (
Original languageEnglish
Article number2552
JournalJournal of Clinical Oncology
Issue number16. suppl.
Pages (from-to)2552
Number of pages1
Publication statusPublished - 2022
Event2022 ASCO annual meeting - McCormick Place, Chicago, United States
Duration: 3. Jun 20227. Jun 2022


Conference2022 ASCO annual meeting
LocationMcCormick Place
Country/TerritoryUnited States

Cite this